Taxanes for advanced non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 12, 2002, Pages 1693-1709

  Ramalingam, Sakkaraiappan ^a   Belani, Chandra P ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic agents; Chemotherapy; Docetaxel; Microtubule stabilisers; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESSENGER RNA; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TENIPOSIDE;

ADVANCED CANCER; ANAPHYLAXIS; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER RECURRENCE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MICROTUBULE; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STANDARD; UNITED STATES; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0036927127     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.12.1693     Document Type: Review

References (113)

1. MOUNTAIN CF, DRESLER CM: Regional lymph node classification for lung cancer staging. Chest (1997) 111:1718-1723.
2. NSCLC Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899-909.
3. SANDLER A, ETTINGER DS: Gemcitabine: single-agent and combination therapy in NSCLC. Oncologist (1999) 4:241-251.
4. CRAWFORD J, O'ROURKE M, SCHILLER JH et al.: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J. Clin. Oncol. (1996) 14:2774-2784.
5. DEPIERRE A, LEMARIE E, DABOUIS G et al.: A Phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am. J. Clin. Oncol. (1991) 14:115-119.
6. DOUILLARD FY, IBRAHIM N, RIVIERE A et al.: Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1995) 14:365a.
7. RAMANATHAN RK, BELANI CP: Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin. Oncol. (1997) 24:440-454.
8. SCHILLER J, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
9. RODRIGUEZ J, PAWEL J, PLUZANSKA A et al.: A multicenter, randomized Phase III study of docetaxel+ cisplatin (DC) and docetaxel + carboplatin (DCB) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:314a.
10. KELLY K, CROWLEY J, BUNN PA et al.: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. (2001) 19:3210-3218.
11. BELANI CP, NATALE RB, LEE JS et al.: Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1998) 17:455a.
12. WANI MC, TAYLOR HL, WALL ME et al.: Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 93:2325-2327.
13. VERWEIJ J, CLAVEL M, LE CHEVALIER B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. (1994) 5:495-505.
14. EISENHAUER EA, VERMORKEN JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 55:5-30.
15. LIEBMANN J, COOK JA, LIPSCHULTZ C et al.: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br. J. Cancer (1993) 68:1104-1109.
16. AOE K, UEOKA H, KIURA K et al.: Synergistic effect of docetaxel and vinorelbine against in vitro growth of a human small-cell lung cancer cell line. Proc. Ann. Mtg. Am. Assoc. Cancer. Res. (1996) 37:1780a.
17. MILAS L, MILAS MM, MANSON KA: Combination of taxanes with radiation: preclinical studies. Sem. Radiat. Oncol. (1999) 9(Suppl. 1):12-26.
18. VACCA A, RIBATTI D, IURLARO M et al.: Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. (2002) 11:103-118.
19. ROWINSKY E, ONETTO N, CANETTA RM et al.: Taxol: the prototypic taxane, an important new class of antitumor agents. Semin. Oncol. (1992) 19:646-662.
20. ROWINSKY EK, EISENHAUER EA, CHAUDHRY V: Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. (1993) 20:1-15.
21. GELDERBLOM H, MROSS K, TEN TIJE AJ et al.: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J. Clin. Oncol. (2002) 20:574-581.
22. GRECO FA: Docetaxel (Taxotere) administered in weekly schedules. Semin. Oncol. (1999) 26(Suppl. 11):28-31.
23. GALINDO E, KAVANAGH J, FOSSELLA F et al.: Docetaxel toxicities: analysis of a single institution experience of 168 patients (623 courses). Proc. Am. Soc. Clin. Oncol. (1994) 13:164a.
24. CHANG AY, KIM K, GLICK J et al.: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst. (1993) 85:388-394.
25. MURPHY WK, FOSSELLA FV, WINN RJ et al.: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst. (1993) 85:384-388.
26. GATZEMEIER U, HECKMAYR M, NEUHAUSS R et al.: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer (1995) 12:S101-S106.
27. TESTER W, JIN PY, REARDON DH et al.: Phase II study of patients with metastatic non small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer (1997) 79:724-729.
28. HAINSWORTH JD, THOMPSON DS, GRECO FA et al.: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. (1995) 13:1609-1614.
29. RANSON M, DAVIDSON N, NICOLSON M et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (2000) 92:1074-1080.
30. BREATHNACH OS, GEORGIADIS MS, SCHULER BS et al.: Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin. Cancer Res. (2000) 6:2670-2676.
31. GEORGIADIS MS, RUSSELL EK, GAZDAR AF et al.: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin. Cancer Res. (1997) 3:449-454.
32. BELANI CP, VAN ECHO DA, AISNER J: Platinum compounds. Current Opin. Oncol. (1989) 1:186-191.
33. BELANI CP, KEARNS CM, ZUHOWSKI EG et al.: A Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. J. Clin. Oncol. (1999) 17:676-684.
34. LANGER CJ, LEIGHTON JC, COMIS RL et al.: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A Phase II toxicity, response, and survival analysis. J. Clin. Oncol. (1995) 13:1860-1870.
35. KEARNS C, BELANI CP, HIPONIA D et al.: Pharmacology of carboplatin and paclitaxel. Semin. Oncol. (1995) 22:1-6.
36. GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al.: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2000) 18:3390-3399.
37. GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Lung Cancer Cooperative Group. J. Clin. Oncol. (1998) 16:2133-2141.
38. LILENBAUM R, HERNDON J, LIST M et al.: Single agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. Proc. Am. Soc. Clin. Oncol. (2002) 21:1a.
39. KELLY K, PAN Z, MURPHY J et al.: A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1997) 3:1117-1123.
40. HUIZING MT, VAN WARMERDAM LJC, ROSING H et al.: Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage IIIB or IV ovarian cancer. J. Clin. Oncol. (1997) 15:1953-1964.
41. BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial. J. Clin. Oncol. (2000) 18:623-631.
42. ROWINSKY EK, JIROUTEK M, BONOMI P et al.: Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin. Cancer Res. (1999) 5:767-774.
43. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann. Oncol. (2000) 11:799-805.
44. CHOY H, PYO H, KIM JS et al.: Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. Expert Opin. Pharmacother. (2001) 2:963-974.
45. AKERLEY W, GLANTZ M, CHOY H et al.: Phase I trial of weekly paclitaxel in advanced lung cancer. J. Clin. Oncol. (1998) 16:153-158.
46. AKERLEY W, HERNDON J, EGORIN MJ et al.: Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:462a.
47. BELANI CP, BARSTIS J, PERRY M et al.: Phase II multicenter randomized trial of weekly paclitaxel administered in combination with carboplatin followed by maintenance paclitaxel versus observation for patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:323a.
48. SOCINSKI MA, SCHELL MJ, BAKRI K et al.: Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer (2002) 95:1265-1273.
49. SCULIER JP, BERGHMANS T, LAFITTE JJ et al.: A Phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer (2002) 37:73-77.
50. KOUMAKIS G, DEMETRI M, BARBOUNIS V et al.: Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a Phase II trial. Lung Cancer (2002) 35:315-317.
51. ROA V, CONNER A, MITCHELL RB et al.: Carboplatin and paclitaxel for previously treated patients with non-small cell lung cancer. Cancer Invest. (1998) 16:381-384.
52. STATHOPOULOS GP, RIGATOS S, MALAMOS NA et al.: Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol. Rep. (1999) 6:797-800.
53. KAVALLARIS M, KUO DYS, BURKHARDT CA et al.: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clinical Invest. (1997) 100:1282-1293.
54. ZAMAN GJR, FLENS MJ, VAN LEUSDEN HR et al.: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA (1994) 91:8822-8826.
55. MONZO M, ROSELL R, SANCHEZ J et al.: Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J. Clin. Oncol. (1999) 17:4786-1793.
56. EISENHAUER EA, LU F, MULDAL A et al.: Predictors and treatment of docetaxel toxic effects. Ann. Oncol. (1994) (Suppl. 5):202.
57. RAMALINGAM S, BONOMI P, DOBBS T et al.: Docetaxel and carboplatin for advanced non-small cell lung cancer: Dose of carboplatin influences outcome. Proc. Am. Soc. Clin. Oncol. (2002) 21:316a.
58. GRALLA RJ, RODRIGUEZ J, VON PAWEL J et al.: Prospective analysis of quality of life (QOL) in a randomized multinational Phase III study comparing docetaxel (D) plus either cisplatin (C) or carboplatin (Cb) with vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:300a.
59. KUBOTA K, WATANABE K, KUNITOH H et al.: Final results of a randomized Phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:296a.
60. GEORGOULIAS V, ARDAVANIS A, AGELIDOU M et al.: Preliminary analysis of a multicenter Phase III trial comparing docetaxel versus docetaxel/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a.
61. SEDERHOLM C: Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: a Phase III study by the Swedish Lung Cancer Study Group. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a.
62. FERRIGNO D, BUCCHERI G: Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer (2000) 29:91-104.
63. SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (2000)18:2095-2103.
64. FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. (2000) 18:2354-2362.
65. GANDARA DR, VOKES E, GREEN M et al.: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a Phase II multicenter trial. J. Clin. Oncol. (2000) 18:131-135.
66. LILENBAUM RC, SCHWARTZ MA, SEIGEL L et al.: Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer (2001) 92:2158-2163.
67. HAINSWORTH JD, BURRIS HA, LITCHY S et al.: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer (2000) 89:328-333.
68. 2 weekly in patients with pretreated non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:310a.
69. SCHUTTE W, NAGEL S, LAUTENSCHLAGER C et al.: Randomized Phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:308a.
70. GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicenter trial. Lancet (2001) 357:1478-1484.
71. VAN MEERBEECK J, SMIT EF, LIANES P et al.: A EORTC randomized Phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:308a.
72. KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. (2002) 20:3578-3585.
73. CHEN YM, PERNG R, LEE YC et al.: Paclitaxel plus carboplarin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable non-small cell lung cancer previously untreated. Ann. Oncol. (2002)13:108-115.
74. TRUMP DL, EGORIN MJ, RAMANATHAN R et al.: A new oral taxane (BMS 275183): Phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. Proc. Am. Soc. Clin. Oncol. (2002) 21:100a.
75. ALBEROLA V, ROSELL R, GONZALEZ-LARRIBA JL et al.: Single agent taxol, 3-hour infusion, in untreated advanced non-small cell lung cancer. Ann. Oncol. (1995) 6:S49-S52.
76. MILLWARD MJ, BISHOP JF, FRIEDLANDER M et al.: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol. (1996) 14:142-148.
77. HAINSWORTH JD, THOMPSON DS, GRECO FA et al.: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. (1995) 13:1609-1614.
78. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer (1995) 75:968-972.
79. LATREILLE J, GELMON KA, HIRSH V et al.: Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs (1998) 16:265-270.
80. CERNY T, KAPLAN S, PAVLIDIS N et al.: Docetaxel (Taxotere) is active in non-small cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer (1994) 70:384-387.
81. FRANCIS PA, RIGAS JR, KRIS MG et al.: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol. (1994) 12:1232-1237.
82. FOSSELLA FV, LEE JS, MURPHY WK et al.: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol. (1994)12:1238-1244.
83. KUNITOH H, WATANABE K, ONOSHI T et al.: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J. Clin. Oncol. (1996) 14:1649-1655.
84. PERNG RP, SHIH JF, CHEN YM et al.: A Phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer. Jpn. J. Clin. Oncol. (2000) 30:429-434.
85. SAARINEN A, JEKUNEN A, HALME M et al.: A Phase II trial of docetaxel in advanced non-small cell lung cancer. Antiancer Drugs (1996) 7:890-892.
86. GRIDELLI C, FRONTINI L, BARLETTA E et al.: Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A Phase II study and review of the literature. Anticancer Res. (2000) 20:1077-1084.
87. MATTSON K, BOSQUEE L, DABOUIS G et al.: Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer (2000) 29:205-216.
88. FOSSELLA FV, LEE JS, SHIN DM et al.: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J. Clin. Oncol. (1995) 13:645-651.
89. PIRKER R, KRAJNIK G, ZOCHBAUER S et al.: Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. Oncol. (1995) 6:833-835.
90. VON PAWEL J, WAGNER H, NIEDERLE N et al.: Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1996) 23:S47-S50.
91. HSU JW, HSU JY, CHIANG CD: Preliminary result of Phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small cell lung cancer in chinese patients. Am. J. Clin. Oncol. (1998) 21:487-490.
92. SAKAI H, YONEDA S, TAMURA T et al.: A Phase II study of paclitaxel plus cisplatin for advanced non-small cell lung cancer in Japanese patients. Cancer Chemother. Pharmacol. (2001) 48:499-503.
93. SORENSEN JB, WEDERVANG K, DOMBERNOWSKY P et al.: Preliminary results of a Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1997) 24:S12-S18.
94. BELLI L, LE CHEVALIER T, GOTTFRIED M et al.: Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1995) 14:1058a.
95. JOHNSON DH, PAUL DM, HANDE KR et al.: Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A Phase II trial. J. Clin. Oncol. (1996) 14:2054-2060.
96. HAINSWORTH JD, URBA WJ, HON JK et al.: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, Phase II trial. Eur. J. Cancer (1998) 34:654-658.
97. LAOHAVINIJ S, MAOLEEKOONPAIROJ S, CHEIRSILPA A et al.: Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer (1999) 26:175-185.
98. CHEN YM, PERNG RP, LEE YC et al.: Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann. Oncol. (2002) 13:108-115.
99. KOSMIDIS PA, MYLONAKIS N, FOUNTZILAS G et al.: Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a Phase II study. Ann. Oncol. (1997) 8:697-699.
100. SCAGLIOTTI G, CRINO L, POZZI E et al.: Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer. Lung Cancer (1999) 25:39-46.
101. LANGER CJ, LEIGHTON JC, COMIS RL et al.: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A Phase II toxicity, response, and survival analysis. J. Clin. Oncol. (1995) 13:1860-1870.
102. BELANI CP, KEARNS CM, ZUHOWSKI EG et al.: A Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. J. Clin. Oncol. (1999) 17:676-684.
103. MUGGIA FM, VAFAI D, NATALE R: Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin. Oncol. (1995) 22:63-66.
104. HELSING M, THANING, L, SEDERHOLM C et al.: Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a Phase II multicentre trial. Joint Lung Cancer Study Group. Lung Cancer (1999) 24:107-113.
105. ZALCBERG J, MILLWARD M, BISHOP J et al.: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. (1998) 16:1948-1953.
106. BELANI CP, BONOMI P, DOBBS TW, et al.: Docetaxel and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC): a multicenter Phase II trial. Clin. Lung Cancer (1999) 1:144-150.
107. GEORGOULIAS V, ANDROULAKIS N, DIMOPOULOS AM et al.: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Oncol. (1998) 9:331-334.
108. LE CHEVALIER T, MONNIER A, DOUILLARD JY et al.: Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. J. Cancer (1998) 34:2032-2036.
109. SCHUETTE W, BORK I, WOLLSCHLAGER B et al.: Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer. Clin. Drug Invest. (2001) 21:161-168.
110. MILLWARD MJ, BISHOP J, LEHNERT M et al.: Phase II trial of docetaxel and carboplatin in advanced NSCLC. Proc. Am. Soc. Clin. Oncol. (1999) 18:517a.
111. ARCENAS A, ANDERSON A, KRASNOW S et al.: Docetaxel/carboplatin combination therapy for stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. (1999) 18:495a.
112. HARVEY J, WINDSOR K, LASKER J et al.: A Phase II study of docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:511a.
113. JAHANZEB M, SARNA G, HIRSCH R et al.: A multicenter Phase II trial of carboplatin and docetaxel in previously untreated advanced non-small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:514a.